Key Takeaways
- Defining year, strong Q4: FY26 was the company's highest-ever annual performance, with Q4 CDMO revenue up 41% YoY and Branded Generics up 46% YoY.[4-5]
- Jammu facility nearing breakeven: The new facility contributed ~₹300 crores in its first full year and is expected to turn EBITDA positive in the coming quarter, a key margin unlock.
- Margins dipped on mix, recovery promised: Q4 EBITDA margin fell to 14.9% due to product mix, but management expects FY27 margins to expand by a few percentage points as Jammu scales.
- API price volatility managed: Cephalosporin API prices stabilized in H2 FY26, and the cost-plus CDMO model largely passes raw material spikes to customers, insulating gross margins. [5-6]
- What to watch next quarter: Whether Jammu actually turns EBITDA positive, the pace of the promised margin expansion, and any further color on the semaglutide "wave 2" launch timeline.
Jammu Facility Ramp-Up
- First full year complete: The Kathua (Jammu) facility generated ~₹300 crores in revenue in FY26, its first full year of operation, with steady progress as marquee customers completed audits and validated stability data.
- Nearing breakeven: In Q4, the facility was nearing EBITDA breakeven; management expects it to become EBITDA positive and begin covering fixed costs in the coming quarter.
- Volume growth confidence: Management is confident of maintaining 20%+ volume growth from FY26 into FY27, with Jammu playing a major role, though a facility-wise breakup was not shared.
- Regulatory milestones: Jammu blocks received PIC/S certification through SMDC Ukraine, adding to the facility's credentials for regulated markets.
- Revenue split undisclosed: Management declined to provide a rough split of Jammu's revenue between CDMO and Branded Generics, stating they do not track business area revenue at a capability level.
Margin Trajectory & Cost Structure
- Q4 margin compressed by mix: EBITDA margin fell to 14.9% in Q4, which management attributed to a change in product mix, while FY26 full-year margin stood at 15.4% with improving operating leverage.
- FY27 expansion promised: Management expects FY27 EBITDA margin to be better than FY26, with a few percentage points of improvement driven by operational leverage as Jammu utilization ramps up.
- PAT to outgrow EBITDA: PAT growth is expected to outpace EBITDA growth because depreciation and interest costs from the Jammu facility are already reflected in the FY26 base, and new project costs will be capitalized rather than flowing to the P&L in FY27.
- Gross margin pressure from mix, not raw materials: Gross margins declined YoY despite the branded business share increasing, due solely to product mix; raw material price increases had no impact on gross margin.
- Baddi expansion to add capacity, not immediate margin: A newly acquired land parcel at Baddi (~₹20-odd crores) will house a general oral solids/liquids facility to address capacity constraints, with capex spread across FY27 and FY28.
Lohariwala: “So what happened in the initial strategy, that is a capitalized cost. So let's say, if we are putting some plant in the next financial year, then the cost of interest is again capitalized. So directly, it will not flow to the P&L. And that's why we are expecting that there is a margin expansion can happen.”
CDMO Business
- 41% YoY Q4 growth: Driven by an increased product portfolio, new customer additions, and deepening wallet share with existing customers across therapeutic categories and dosage forms. [4-5]
- Customer base diversification: The CDMO business now serves over 350 clients, including several leading Indian pharmaceutical companies, and is not over-reliant on any single customer or product.
- Cost-plus pricing shields margins: CDMO contracts are structured on a cost-plus basis, so API price spikes from the Middle East conflict were largely passed through to customers. [5-6]
- Volume vs realization split undisclosed: Management did not provide a split of CDMO revenue growth into volume and realization, offering only facility-level commentary (Baddi grew ~35% YoY through volumes).
- Pipeline moving up the value chain: The company is expanding into complex and niche segments including peptides, new dosage forms, BFS, respules, beta-lactam, and penems, supported by a strong R&D pipeline.
- Export vs domestic split unavailable: Management declined to provide a quantitative breakup of CDMO growth between domestic and export markets.
Branded Generics & Exports
- 46% YoY Q4 growth: Management called it a testament to distribution strategies, with growth coming from all business areas.
- Geographic mix roughly estimated: Management offered a rough estimate of 70% domestic, 30-35% exports for the Branded Generics business, while noting they do not normally track geography at the business-area level.
- Regulated market push underway: The company is filing products in Canada, the UK, Europe, and Australia, expecting healthy growth with better margins from these territories, though no specific timeline was given for a visible contribution improvement.
- Export growth drivers opaque: Export growth was ~₹200-odd crores, but management declined to split this between Branded Generics and CDMO, or to address whether the export business specifically has customer concentration risk.
Product Pipeline & Strategic Bets
- Semaglutide "wave 2" strategy: Initial R&D work on semaglutide has yielded positive results; the company is working on exhibit batches and filing to the local FDA, aiming to be ready for the second wave of market entry rather than competing for first-to-market.
- Generics-focused R&D model: The pipeline targets multiple products going off-patent, using reverse engineering and an early-launch strategy; as a CDMO, cost-sharing with front-lining partners is an advantage.
- Baddi facility expansion: The newly acquired land will address capacity constraints in the existing Baddi portfolio with a general oral tablet/capsule/liquid facility, distinct from Jammu-type products. Capex will be incurred across FY27 and FY28.
- Regulatory compliance as a moat: All facilities are compliant with Schedule M and international regulations, positioning the company to benefit as non-compliant competitors face headwinds.
Lohariwala: “So we will not be -- as the product is already launched, we will -- we are not in the race of the initial launching and all that. So we will be ready with the wave 2 type concept.”
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | Confident in ability to deliver 20%+ revenue growth | FY27 |
| EBITDA growth | Expected to outperform revenue growth as Jammu utilization ramps | FY27 |
| PAT growth | Expected to outpace EBITDA growth, aided by fixed depreciation and interest already in base | FY27 |
| Margin expansion | EBITDA margin to be better than FY26; a few percentage points improvement expected | FY27 |
| Jammu EBITDA positive | Jammu to become EBITDA positive and start covering fixed costs | Coming quarter (Q1 FY27) |
| Jammu volume growth | Confident of maintaining 20%+ volume growth from FY26 to FY27 | FY27 |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Consolidated revenue | ₹447.8 cr, +42% YoY |
| CDMO revenue | ₹314.8 cr, +41% YoY |
| Branded Generics revenue | ₹133 cr, +46% YoY |
| EBITDA | ₹66.7 cr, +31% YoY; margin 14.9% |
| PAT | ₹38.1 cr, +29% YoY |
| Exports contribution | 28% of revenue |
| FY26 consolidated revenue | ₹1,630 cr, +31% YoY |
| FY26 CDMO revenue | ₹1,133 cr, +24% YoY |
| FY26 Branded Generics revenue | ₹497 cr, +51% YoY |
| FY26 EBITDA | ₹250.3 cr, margin 15.4% |
| FY26 PAT | ₹140.9 cr, +10% YoY |
| FY26 exports contribution | 31% of revenue |
| Jammu facility FY26 revenue | ₹300 cr |
| Jammu facility Q4 exit run-rate | ₹90 cr+ |
| Sharon Bio FY26 revenue | ~₹240 cr |
| FY27 volume growth guidance | 20%+ over FY26 |
| New Baddi plant capex (planned) | ₹150–170 cr |
| New Baddi plant revenue potential | ₹450–500 cr at optimum |
| Customer base | 350+ clients |
| Branded Generics domestic/export split | ~70% domestic, 30–35% exports |
| Ex-Jammu EBITDA margin | ~18–18.2% (per an analyst's math) |